milrinone has been researched along with Hypertrophy, Left Ventricular in 5 studies
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to test the hypothesis that local myocardial work and O2 consumption would respond differentially to milrinone, a selective cyclic AMP-phosphodiesterase inhibitor, in left ventricular hypertrophy due to differences in myocardial cyclic AMP-phosphodiesterase activity." | 7.69 | Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. ( Cheinberg, BV; Chiu, WC; Kedem, J; Scholz, PM; Tse, J; Weiss, HR, 1994) |
| "The aim was to test the hypothesis that local myocardial work and O2 consumption would respond differentially to milrinone, a selective cyclic AMP-phosphodiesterase inhibitor, in left ventricular hypertrophy due to differences in myocardial cyclic AMP-phosphodiesterase activity." | 3.69 | Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. ( Cheinberg, BV; Chiu, WC; Kedem, J; Scholz, PM; Tse, J; Weiss, HR, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dasgupta, S | 1 |
| Qasim, A | 1 |
| Aly, AM | 1 |
| Jain, SK | 1 |
| Zhang, Q | 1 |
| Lazar, M | 1 |
| Molino, B | 1 |
| Rodriguez, R | 1 |
| Davidov, T | 1 |
| Su, J | 1 |
| Tse, J | 2 |
| Weiss, HR | 3 |
| Scholz, PM | 3 |
| Chiu, WC | 1 |
| Kedem, J | 1 |
| Cheinberg, BV | 1 |
| Jain, P | 1 |
| Hughes, M | 1 |
| Korlipara, G | 1 |
| Lillis, O | 1 |
| Dervan, JP | 1 |
| Cohn, PF | 1 |
| Leone, RJ | 1 |
5 other studies available for milrinone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Mother With Diabetes Mellitus and Infant With Hypertrophic Obstructive Cardiomyopathy: Milrinone Precluded Need for Extracorporeal Membrane Oxygenation.
Topics: Biomarkers; Blood Glucose; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Diabetes, Gestational; | 2017 |
Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure.
Topics: Adenine; Animals; Body Weight; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Dogs; Drug Interactions; | 2005 |
Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aortic Valve Stenosis; Disease Models, Animal; Dogs; H | 1994 |
The effects of chronic oral milrinone therapy on early postinfarction left ventricular remodeling.
Topics: Administration, Oral; Analysis of Variance; Animals; Cardiotonic Agents; Disease Models, Animal; Dru | 1993 |
Positive functional effects of milrinone and methylene blue are not additive in control and hypertrophic canine hearts.
Topics: Animals; Cyclic AMP; Cyclic GMP; Dogs; Drug Combinations; Drug Synergism; Enzyme Inhibitors; Guanyla | 1998 |